直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
Li Feng, Ph.D.
Partner
More
vCard
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
+1 202 408 4382
li.feng@finnegan.com li.feng@finnegan.com

Li Feng, Ph.D.

Partner

  • +1 202 408 4382 +1 202 408 4382
  • li.feng@finnegan.com li.feng@finnegan.com
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
  • vCard

Li Feng, Ph.D., practices all aspects of patent law, including patent litigation before U.S. district courts, post-grant proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), and global patent procurement. She routinely handles matters related to a wide range of technologies, including small molecule and biologic pharmaceuticals, diagnostics, biotechnology, chemicals, agricultural sciences, renewable energy, nanotechnology, cosmetics, and medical devices. Years of doctoral and industry research give Li a practical understanding of the innovation process.

Li counsels pharmaceutical companies on pre-litigation and litigation matters under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA). She has successfully represented clients in contentious matters in the United States and coordinated litigation and opposition strategies in other jurisdictions. Li has extensive experience in preparing and prosecuting U.S. patent applications, coordinating and managing non-U.S. prosecution, and developing strategies for global patent portfolio management and planning. She regularly provides legal opinions on patentability, validity, enforceability, and infringement, and conducts evaluations for due diligence and freedom to operate (FTO) assessments.

 

Prior to her legal career, Li conducted research in lipid cell signaling using fluorescent and radiolabeled molecular probes and was a prolific author of scientific publications. Her background in both chemistry and biology enables her to effectively communicate with clients in the life sciences sectors.

 

Li frequently writes and speaks about intellectual property topics. She currently co-leads Finnegan FORWARD.

Et Cetera

  • Fellow of Leadership Council on Legal Diversity, 2015.
  • Extern to Chief Justice Matthew B. Durrant at the Utah Supreme Court, 2008.

Experience

Nanosys, Inc. v. The Board of Trustees of the University of Arkansas et al.

Represented the patent owner in an inter partes review before the PTAB and obtained a favorable ruling.

IPR2020-00503, PTAB, Judges Abraham, Guest, Heaney

Biogen International GmbH v. Teva Pharmaceuticals USA, Inc.

Represented Biogen in a Hatch-Waxman litigation involving twenty-eight companies seeking FDA approval to market generic versions of Tecfidera®.

1:17-cv-00829, D. Del., Judge Noreika
1:17-cv-00116, N.D.W. Va., Judge Keeley

Mylan Pharmaceuticals Inc. et al. v. Biogen MA Inc. et al.

Represented Biogen in an inter partes review before the PTAB and obtained a favorable ruling for a patent covering Tecfidera®.

IPR2018-01403, PTAB, Judges Chagnon, Harlow, Snedden

Coalition for Affordable Drugs V LLC v. Biogen MA Inc.

Represented Biogen in an inter partes review before the PTAB and obtained a favorable ruling for a patent covering Tecfidera®.

IPR2015-01086, -01136, -01993, PTAB, Judges Gardener-Lane, Katz, Schafer

Certain Sulfentrazone, Sulfentrazone Compositions, and Processes for Making Sulfentrazone

Represented agro-chemical companies at the International Trade Commission and obtained a favorable ruling.

337-TA-914, ITC, Judge Lord

Forward Pharma IP APS v. Biogen MA, Inc. 

Represented Biogen in an interference proceeding before the PTAB and obtained a favorable ruling for a patent covering Tecfidera®.

106,023, PTAB, Judges Gardner-Lane, Katz, Schafer

Lo v. Quake

Represented Sequenom, Inc. et al in three interference cases before the PTAB of the USPTO and obtained favorable rulings relating to Dr. Dennis Lo’s inventions on noninvasive prenatal diagnosis.

105,920; 105,923; 105,924, PTAB, Judges Gardner-Lane, Katz, Moore

Voglewede v. Lee

Represented LG (Lee) in a patent interference provoked by competitor Whirlpool (Voglewede) attempting to challenge LG refrigerator patents; judgment entered against Whirlpool and in favor of client LG.

Int. No. 105711, BPAI, Judge Lee

Nanosys, Inc. v. The Board of Trustees of the University of Arkansas et al.

Represented the patent owner in an inter partes review before the PTAB and obtained a favorable ruling.

IPR2020-00503, PTAB, Judges Abraham, Guest, Heaney

Biogen International GmbH v. Teva Pharmaceuticals USA, Inc.

Represented Biogen in a Hatch-Waxman litigation involving 28 companies seeking FDA approval to market generic versions of Tecfidera®.

1:17-cv-00829, D. Del., Judge Noreika
1:17-cv-00116, N.D.W. Va., Judge Keeley

Mylan Pharmaceuticals Inc. et al. v. Biogen MA Inc. et al.

Represented Biogen in an inter partes review before the PTAB and obtained a favorable ruling for a patent covering Tecfidera®.

IPR2018-01403, PTAB, Judges Chagnon, Harlow, Snedden

Coalition for Affordable Drugs V LLC v. Biogen MA Inc.

Represented Biogen in an inter partes review before the PTAB and obtained a favorable ruling for a patent covering Tecfidera®.

IPR2015-01086, -01136, -01993, PTAB, Judges Gardener-Lane, Katz, Schafer

Certain Sulfentrazone, Sulfentrazone Compositions, and Processes for Making Sulfentrazone

Represented agro-chemical companies at the International Trade Commission and obtained a favorable ruling.

337-TA-914, ITC, Judge Lord

Forward Pharma IP APS v. Biogen MA, Inc. 

Represented Biogen in an interference proceeding before the PTAB and obtained a favorable ruling for a patent covering Tecfidera®.

106,023, PTAB, Judges Gardner-Lane, Katz, Schafer

More

Insights

Conference

10th IP Forefront Pharma Forum 10th IP Forefront Pharma Forum

September 17-19, 2025

Shanghai

Conference

2024 AIPPI World Congress 2024 AIPPI World Congress

October 19-22, 2024

Hangzhou

Conference

9th IP Forefront Pharma Forum 2024 9th IP Forefront Pharma Forum 2024

October 16-18, 2024

Suzhou

Conference

Biologics US 2024 Biologics US 2024

October 3-4, 2024

San Diego

Webinar

Building a Strong ADC Patent Portfolio – From Prosecution and Litigation Perspectives Building a Strong ADC Patent Portfolio – From Prosecution and Litigation Perspectives

May 15, 2024

Webinar

Conference

3rd Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA 3rd Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA

October 10-26, 2023

Virtual

More

News

Award/Ranking

Finnegan Wins Best Diversity Initiative at The American Lawyer 2024 Industry Awards

Finnegan Wins Best Diversity Initiative at The American Lawyer 2024 Industry Awards

November 14, 2024

Award/Ranking

Finnegan Named a Finalist for The American Lawyer Industry Awards Finnegan Named a Finalist for The American Lawyer Industry Awards

September 3, 2024

The American Lawyer

Announcement

Finnegan Announces 2023 Mentors of the Year Finnegan Announces 2023 Mentors of the Year

December 29, 2023

Commentary

China's Patent Linkage System Is Finally Up and Running China's Patent Linkage System Is Finally Up and Running

July 15, 2021

Intellectual Asset Management (IAM)

Press Release

Finnegan Ranks in the Top 15 as a 2017 Working Mother "Best Law Firm for Women" Finnegan Ranks in the Top 15 as a 2017 Working Mother "Best Law Firm for Women"

July 25, 2017

Working Mother

Press Release

Finnegan Announces Eleven New Partners Finnegan Announces Eleven New Partners

January 3, 2017

More

Professional Activities

  • American Intellectual Property Law Association (AIPLA)
  • International Association for the Protection of Intellectual Property (AIPPI)
    (member of Standing Committee on Pharma and Biotechnology, 2014-present)
  • Sino-American Pharmaceutical Professionals Association (SAPA)
    (executive council, 2021-present)
Admissions and Education

Admissions

  • U.S. Patent and Trademark Office
  • California
  • District of Columbia
  • U.S. Court of Appeals, Federal Circuit

Education

University of Utah
J.D., with high honors, 2008
Ph.D., Medicinal Chemistry, 1999

Peking University
M.S., Physical Chemistry, 1993
B.S., Chemistry, 1990

Languages

  • Chinese (Mandarin)

Li's Practices

Appeals, Issues, and Legal Strategy
Appeals from the PTAB
Federal Circuit and Supreme Court Appeals
Diligence, Licensing, and Opinions
Due Diligence
Freedom to Operate Opinions
Opinions and Counseling
Global IP Enforcement, Litigation, and Trials
Branded Hatch-Waxman (ANDA) Litigation and Trials
Federal Circuit and Supreme Court Appeals
ITC Section 337 Investigations and Trials
Patent Litigation and Trials
Patent Office Invalidation Proceedings
Derivations
Ex Parte Reexamination (EPR)
Interferences
PTAB Invalidation Proceedings: IPR and PGR
Prosecution and Portfolio Management
Appeals to the PTAB
Ex Parte Reexamination (EPR)
IP Portfolio Management
Patent Drafting and Prosecution
Patent Reissues

Li's Industries

AI, Electronics, and Information Technology
Nanotechnology
Chemicals, Industrials, and Materials
Chemical
Energy
Clean Energy and Renewables
Oil and Gas
Life Sciences
Biologics
Biotechnology
Medical Device and Diagnostics
Pharmaceutical

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP